Crosstalk between hydroxytyrosol, a major olive oil phenol, and HIF-1 in MCF-7 breast cancer cells by Calahorra, J. et al.
1Scientific RepoRtS |         (2020) 10:6361  | https://doi.org/10.1038/s41598-020-63417-6
www.nature.com/scientificreports
crosstalk between hydroxytyrosol, 
a major olive oil phenol, and HIF-1 
in MCF-7 breast cancer cells
Jesús calahorra1, esther Martínez-Lara1, José M. Granadino-Roldán  2, Juan M. Martí3, 
Ana cañuelo1, Santos Blanco  1, f. Javier oliver3 & eva Siles  1*
Olive oil intake has been linked with a lower incidence of breast cancer. Hypoxic microenvironment 
in solid tumors, such as breast cancer, is known to play a crucial role in cancer progression and in the 
failure of anticancer treatments. HIF-1 is the foremost effector in hypoxic response, and given that 
hydroxytyrosol (HT) is one of the main bioactive compounds in olive oil, in this study we deepen 
into its modulatory role on HIF-1. Our results in MCF-7 breast cancer cells demonstrate that HT 
decreases HIF-1α protein, probably by downregulating oxidative stress and by inhibiting the PI3K/
Akt/mTOR pathway. Strikingly, the expression of HIF-1 target genes does not show a parallel 
decrease. Particularly, adrenomedullin and vascular endothelial growth factor are up-regulated by 
high concentrations of HT even in HIF-1α silenced cells, pointing to HIF-1-independent mechanisms 
of regulation. In fact, we show, by in silico modelling and transcriptional analysis, that high doses of 
HT may act as an agonist of the aryl hydrocarbon receptor favoring the induction of these angiogenic 
genes. In conclusion, we suggest that the effect of HT in a hypoxic environment is largely affected by its 
concentration and involves both HIF-1 dependent and independent mechanisms.
Breast cancer is the most common cancer diagnosed in women and the second leading cause of death from can-
cer among them1. Approximately 25%–40% of invasive breast cancers exhibit hypoxic regions in which oxygen 
pressure is diminished2. This hypoxic microenvironment favors cancer progression and metastasis and should be 
taken into account in cancer research.
Hypoxia inducible factor-1 (HIF-1) is the key factor in the adaptive response to hypoxia. The binding of HIF-1 
to hypoxic response elements (HREs) regulates the transcription of a plethora of genes involved, among others, in 
glucose metabolism, cell proliferation, cell survival and angiogenesis3. Therefore, HIF-1 overexpression is strongly 
related with poor prognosis and resistance to chemotherapy and radiotherapy4,5. HIF-1 is a heterodimeric tran-
scription factor composed by an oxygen-sensitive α subunit, HIF-1α, and a constitutive subunit, ARNT. HIF-1α 
transcription, translation and stability are highly regulated in an oxygen-dependent and independent manner. 
At the transcriptional level, HIF-1α expression is regulated by different transcription factors such as Sp1, NF-κB, 
Erg1 and by HIF-1 itself6–8. The translation of HIF-1α mRNA can be upregulated through the PI3K/Akt/mTOR 
pathway. Particularly, mTOR when activated by Akt, mediates the phosphorylation of p70 S6 kinase (S6K) that 
induces HIF-1α translation through the ribosomal protein S69. Once translated, and under normoxic condi-
tions, HIF-1α subunit is quickly degraded due to the activity of the prolyl-4-hydroxylases (PHDs) that label 
HIF-1α enabling its ubiquitination by the pVHL and its degradation in the proteasome. Conversely, hypoxic 
conditions inhibit PHDs activity and promote HIF-1α stabilization. Besides this oxygen-dependent regulation 
of HIF-1α, reactive oxygen species (ROS) and nitric oxide (NO), crucial in tumorigenesis and particularly high 
in cancer cells, also contribute to the stabilization of HIF-1α by inhibiting PHDs activity under both hypoxic 
and normoxic conditions10,11. Finally, the transcriptional activity of HIF-1 can be modulated by the factor inhib-
iting HIF-1 (FIH) which hydroxylates a critical asparagine residue (Asn-803), in an oxygen-dependent manner, 
blocking coactivator recruitment12. HIF-1α is also dependent on the expression and activity of Poly(ADP-ribose) 
polymerase-1 (PARP-1)13,14, a nuclear, zinc-finger, DNA-binding protein activated in response to oxidative and 
nitrosative stress. This enzyme plays an important role in a number of processes such as DNA repair, chromatin 
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remodeling, transcription or regulation of the cell cycle, among others15. PARP inhibition has been demonstrated 
to exert beneficial effects hindering prometastasic activities and adaptation of tumor to different microenviron-
ments such as hypoxia16.
Lifestyle factors play a significant role in the risk of suffering breast cancer17. The PREDIMED study, a large 
dietary intervention trial, showed the beneficial effect of a Mediterranean diet supplemented with extra-virgin 
olive oil (EVOO) in the primary prevention of breast cancer18. Olive oil is mainly composed of fatty acids, par-
ticularly oleic acid, but its mechanical extraction at temperatures lower than 30 °C also afford a high concentra-
tion of different minor components, such as phenols. The main phenolic alcohol is hydroxytyrosol (HT). Several 
studies have demonstrated the beneficial properties of this compound in a number of models and cancer linked 
events19, particularly in breast cancer20–22. In fact, we have recently described that hypoxia modulates the anti-
oxidant effect of HT in MCF-7 breast cancer cells23. With this background, and considering the importance of 
hypoxia and HIF-1 in breast cancer progression and response to anticancer treatments, the aim of the present 
study is to investigate the effect of HT in the expression and transcriptional activity of this protein. Our results 
indicate that in hypoxic MCF-7 breast cancer cells, HT decreases the expression of HIF-1α, an effect probably 
linked to its antioxidant action and to the down-regulation of the PI3K/Akt/mTOR pathway. Moreover, we show 
that at high concentrations HT can even act as an AHR agonist.
Results
Effect of HT on hypoxic MCF-7 cell viability. We previously reported23, by using the sulforhodamine 
B assay, that the treatment of hypoxic MCF-7 cells with concentrations of HT up to 400 µM did not affect cell 
proliferation. In order to further corroborate the absence of toxicity of the HT concentrations used in this study 
(0–200 µM), we performed trypan blue exclusion (cell viability, Fig. 1a) and Annexin-V/IP FACS (apoptosis, 
Fig. 1b) assays. The results revealed no significant changes in viable nor apoptotic or necrotic cells, confirming the 
absence of a toxic effect of HT in our experimental conditions.
HT does not affect nitric oxide levels during hypoxia. We have described23 that a sub-cytotoxic treat-
ment of hypoxic MCF-7 cells with HT (5–200 μM, 16 h) decreased the oxidative stress level. NO is also crucial 
in the response to hypoxia. Therefore, we have evaluated the effect of those same concentrations of HT in NO 
production. Conversely to what we previously described for ROS, HT did not affect NO levels in a significant 
manner (Fig. 1c).
PARP-1 activity is decreased by high doses of HT. ROS and NO damage DNA and modulate the activ-
ity of PARP-1, a protein largely involved in cancer progression that also regulates HIF-1α response. To assess 
whether the antioxidant effect of HT treatment decreased the expression and activity of this enzyme, we evaluated 
PARP-1 levels and PARylated proteins by using specific antibodies. As shown in Fig. 2, the expression of PARP-1 
was increased in hypoxic conditions but returned to basal levels when cells were treated with concentrations of 
HT equal to or greater than 75 µM. Similarly, PARylated proteins in hypoxic cells were also decreased by HT but 
only at 200 µM.
HT reduces HIF-1α stability in a dose dependent manner, in part, through the mTOR pathway. 
Although no changes were detected in NO levels (Fig. 1c), the impact of HT treatment on both oxidative stress 
and PARP-1 led us to evaluate the mRNA and protein level of HIF-1α. No effects were detected on the expression 
of HIF-1α mRNA, suggesting that HT does not modulate the transcription of this gene (Fig. 3a). However, the 
western-blot analysis revealed that HT was able to reduce HIF-1α protein levels in a dose dependent manner 
from 50 µM to 200 µM (Fig. 3b). In order to further investigate the mechanism underlying this effect, we analyzed 
the impact of HT on the activation of the mTOR pathway. The active form of mTOR (p-mTOR) was decreased by 
treatment with HT 200 µM (Fig. 3c and Supplementary Fig. 1a). Its downstream activated target p-S6 (Fig. 3d and 
Supplementary Fig. 1b) was reduced even at lower concentrations (HT 75, 100 and 200 µM).
HIF-1 targets are up-regulated by high concentrations of HT. We next evaluated the effect of HT 
on the transcriptional activity of HIF-1. For that purpose, we analyzed the mRNA levels of the angiogenic tar-
gets adrenomedullin (AM) and vascular endothelial growth factor (VEGF), and of the metabolic targets glucose 
transporter-1 (GLUT-1) and lactate dehydrogenase A (LDHA). As expected, the expression of all these genes was 
up-regulated under hypoxia (Fig. 4). Surprisingly, and despite HIF-1α protein was down-regulated by HT treat-
ment, the two highest concentration of this phenol (100 and 200 µM) promoted the up-regulation of AM, VEGF 
and GLUT-1. Hence, the transcriptional activity of HIF-1 and the protein levels of HIF-1α do not follow a similar 
pattern of response when MCF-7 cells are treated with high concentrations of HT.
The up-regulation of HIF-1α targets by HT is not due to FIH inhibition. The transcriptional activity 
of HIF-1 is modulated by FIH. The opposite effect of HT in the expression and transcriptional activity of HIF-1 
led us to evaluate the influence of this phenol on FIH (Fig. 4e). No changes in the expression of this protein were 
observed suggesting that the up-regulation of AM, VEGF and GLUT-1 cannot be attributed to a lower expression 
of FIH.
GLUT-1 but not AM and VEGF overexpression by HT, is HIF-1α dependent. AM, VEGF and 
GLUT-1 have been consistently described as HIF-1 target genes. However, the HIF-1 pathway did not seem to 
explain their overexpression after treatment with HT 100 and 200 µM. In order to determine the implication of 
HIF-1 in such overexpression we analyzed whether the up-regulation of AM, VEGF and GLUT-1 persisted after 
knocking down HIF-1α (Fig. 5a). As shown in Fig. 5b, the silencing of HIF-1α abrogated the HT-induced overex-
pression of GLUT-1. However, AM and VEGF genes remained overexpressed in HT-treated cells after silencing 
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HIF-1α (Fig. 5c, d). These results indicate that HT exerts its transcriptional regulation of AM, VEGF through 
HIF-1-dependent and independent mechanisms.
HIF-1-independent pathways also mediate the effect of HT on the hypoxic response. Apart 
from HIF-1, HIF-2 is also involved in the up-regulation of certain genes in response to a hypoxic stimulus. Thus, 
we next addressed the possible involvement of HIF-2 in the transcriptional response to HT. For that purpose, we 
quantified the expression of the specific HIF-2 target Oct-4 in hypoxic HT-treated cells. As shown in Fig. 6a, HT 
produced no effect on the mRNA level of this gene, suggesting that HIF-2α is not involved in the up-regulation 
of AM and VEGF. It has been previously reported that AM and VEGF genes contain xenobiotic response ele-
ments (XRE)24,25 and therefore can be regulated by the aryl hydrocarbon receptor (AHR). CYP1A1 is a sensitive 
marker of AHR activation and we found that it was intensely overexpressed at high HT doses (Fig. 6b). The AHR 
Figure 1. HT does not affect cell viability or nitric oxide levels in hypoxic conditions. (a) Cell viability 
measured as ratio of living cells (trypan blue unstained cells) relative to normoxic non HT-treated cells. 
(b) Representative dot plots of Annexin V/PI FACS analysis: Q1, necrotic cells (Annexin V negative and PI 
positive); Q2, late apoptotic cells (Annexin V and PI positive); Q3, viable cells (Annexin V and PI negative cells) 
and Q4, early apoptotic cells (Annexin V positive and PI negative cells). (c) NO levels (nmol/mg of protein) 
relative to normoxic HT-untreated cells. Values represent the mean ± SD from three independent experiments.
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repressor (AHRR) is also known to be induced in response to AHR activation26 and, in agreement with the previ-
ous result, its expression was also induced at high HT concentrations (Fig. 6c). These results seem to indicate that 
at high concentrations HT could act as an AHR ligand, inducing AM and VEGF expression. AHR and HIF-1α 
must heterodimerize with ARNT to carry out its transcriptional activity. Therefore, by silencing ARNT the effect 
of both HIF-1 and AHR would be concomitantly abolished. As shown in Fig. 7b, the effect of HT on CYP1A1 was 
almost completely abolished in ARNT-silenced hypoxic cells, further corroborating that at high concentrations 
HT binds and activates the AHR pathway. However, the effect of HT on AM or VEGF although significantly 
decreased was not completely abrogated (Figs. 7c and 7d), suggesting the involvement of additional mechanisms 
of regulation, not linked with ARNT.
In silico modelling of HT interaction with AHR. The large central pocket of the AHR PAS-B domain 
has been shown to promiscuously bind a number of toxic halogenated aromatic hydrocarbons, polycyclic aro-
matic hydrocarbons, and other natural, endogenous or synthetic agonists and antagonists27–29, being 2,3,7,8-tet
rachlorodibenzo-p-dioxin (TCDD) the most potent ligand. In order to support our results pointing that HT is 
an AHR ligand, we performed a docking analysis. As it has been shown that there exist important differences 
between the apo and holo structures of the HIF-2α PAS-B domain, used as template for homology modelling 
of the AHR PAS-B domain30,31, we obtained a model for our docking analysis using three holo structures of the 
HIF-2α domain32. We have used and compared two different docking methodologies, one rigid docking that 
uses a pre-defined binding cavity and the Autodock Vina program33, and another one that does not need the 
binding pocket to be defined, based on deep neural networks, using the web program Bindscope34. The first 
methodology rendered ten possible poses that were scored both with the Autodock Vina scoring function and 
with 3D-convolutional neural networks, using the web program KDEEP35. The two best-scored consensus poses 
are shown, together with the pose obtained by Bindscope, in Fig. 8. Interestingly, Bindscope, which is not biased 
by a pre-defined binding site, predicted HT to interact with the same parts of the protein of our defined binding 
site, although this pose reflects a different orientation as compared to those obtained with Autodock Vina, which 
showed two poses in which the main difference is which OH group is establishing a hydrogen bond with GLY321. 
In all cases, the poses predicted for HT establish interactions with residues which have been proven to form the 
so-called TCDD binding fingerprint36 or others proved to be important for binding37,38 (3,4 and 5 of these resi-
dues interacting with HT for the two poses from Autodock Vina and the pose from Bindscope, respectively). The 
poses obtained with Autodock Vina agreed in exhibiting a previously described crucial π-π interaction between 
Figure 2. HT decreases PARP-1 protein level and activity. (a) Densitometric quantifications of PARP-1, protein 
level relative to α-tubulin (α-Tub). A representative immunoblot is shown. Values represent the mean ± SD 
from three independent experiments. Statistically significant differences with the corresponding non-treated 
normoxic cells: *p < 0.05. Statistically significant differences with the corresponding non-treated hypoxic cells: 
##p < 0.01. (b) α-PAR representative immunoblot.
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HT and PHE29536, also obtained in previous docking experiments39. Overall these docking results support the 
findings of HT as ligand of human AHR.
Discussion
The Mediterranean diet has been linked to a lower incidence of different types of cancer, and particularly of breast 
cancer18,20,22,40. In a previous study we demonstrated that HT, the main EVOO phenolic compound in olive oil 
and a recognized nutraceutical, modulates the oxidative response to hypoxia of MCF-7 cells23, a breast cancer cell 
line consistently used in the literature to assess the effect of this phenol. In the present study, and considering the 
crucial role of HIF-1 in hypoxia and in cancer prognosis, we have deepened into the modulatory effect that this 
phenol exerts in the response of the HIF-1 pathway.
NO and ROS up-regulates HIF-1α levels by impairing PHDs and its pVHL-mediated degradation11,41. The 
effect of HT on the production of NO has been previously reported in a number of studies. Although some of 
them show that HT results ineffective in reducing NO production42, most of them demonstrate that this phenol 
down-regulates NO levels, and point to the inhibition of the iNOS isoform as the plausible mechanism underlying 
this effect43. However, these studies were carried out in cells grown in normoxia and the data about the effect that 
HT exerts in NO production in hypoxic cells are scarce. We reported44 that in hypoxic non tumor cells NO levels 
were decreased by treatment with this phenol (100 and 200 µM). Breast cancer cells exhibit NO levels that are par-
ticularly high, and decreasing those level would help to counteract several malignancy-related effects including 
angiogenesis, apoptosis, cell cycle, invasion, and metastasis45. In this study we show that HT is unable to exert 
any effect on NO levels, suggesting that the plausible inhibition of iNOS is overwhelmed in hypoxic MCF-7 cells.
PARP-1 is the funding and most studied member of a family of proteins which catalyzes the synthesis and 
transfer of negatively charged ADP-ribose moieties to a number of target protein substrates that result PARylated. 
PARP-1 activity is induced by oxidative and nitrosative stress and the crucial role of this protein in the response 
to hypoxia, both in non-tumor and tumor cells, has been extensively described by our group14,46,47. Particularly, 
Figure 3. HT down-regulates HIF-1α in a dose dependent manner: m-TOR pathway involvement (a) Effect 
of HT on HIF-1α mRNA levels relative to hypoxic non HT-treated cells after normalization against PPIA. 
(b) Densitometric quantifications of HIF-1α relative to α-tubulin protein level (α-Tub). Densitometric 
quantifications of p-mTOR (c) and p-S6 (d) relative to unphosphorylated corresponding proteins 
(Supplementary Fig. 1). A representative immunoblot is shown. Values represent the mean ± SD from three 
independent experiments. Statistically significant differences with the corresponding non-treated normoxic 
cells: **p < 0.01. Statistically significant differences with the corresponding non-treated hypoxic cells: #p < 0.05, 
##p < 0.01, ###p < 0.001.
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we have reported that the inhibition of PARP-1 decreases the response of HIF-1α. Pharmacological inhibition 
of PARP-1 provides protection from oxidative stress-associated tissue injury, down-regulates the inflamma-
tory response and is also beneficial in cancer treatment by mechanisms such as selective killing of homolo-
gous recombination-deficient tumor cells, down-regulation of tumor-related gene expression (e.g. AP-1 and 
NF-κB-mediated transcription) and apoptotic threshold in the co-treatment with chemo and radiotherapy48. In 
fact, it is currently being used to treat some breast cancers. There is strong evidence in support of the concept that 
hypoxia increases both the expression and the activity of PARP-1, contributing to tumor malignancy. Hence, the 
down-regulation of PARP-1 by HT would be potentially beneficial in cancer patients, e.g. it could counteract the 
cardiovascular and musculoskeletal complications associated to anti-cancer therapies. Our results corroborate 
Figure 4. The effect of HT on HIF-1 targets does not parallel HIF-1α expression. AM (a), VEGF (b), GLUT-1 
(c) and (d) LDHA mRNA levels. Results are expressed as mRNA expression relative to normoxic non HT-
treated cells after normalization against PPIA. (e) The up-regulation of HIF-1α targets by HT is not due to FIH 
inhibition. Densitometric quantifications of FIH protein level relative to α-tubulin (α-Tub). A representative 
immunoblot is shown. Values represent the mean ± SD from three independent experiments. Statistically 
significant differences with the corresponding non-treated normoxic cells: *p < 0.05, **p < 0.01, ***p < 0.001. 
Statistically significant differences with the corresponding non-treated hypoxic cells: ##p < 0.01, ###p < 0.001.
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the up-regulation of PARP-1 expression and activity in hypoxic MCF-7 cells, and demonstrate that HT treatment 
decreases both. However, these results although positive, cannot be exclusively linked to the antioxidant effect of 
HT, as they are achieved at concentrations (≥75 µM) clearly over the antioxidant ones (≥5 µM)23. PARP-1 is also 
regulated by a number of microRNAs49,50, and HT is known to modulate the expression of these small non-coding 
RNA molecules51. Thus, this mechanism could be a plausible additional contributor to PARP-1 down-regulation. 
Strikingly, PARylated proteins did not decrease in the same manner as PARP-1. This unparallel response could be 
due to the activity of other PARP proteins, such as PARP-2, also involved in DNA repair and gene transcription.
Breast cancer patients exhibit significantly high HIF-1α levels, which correlate with more aggressive cancer 
features, and particularly with a poor disease free and overall survival52. Our results showed that HT (50–200 µM) 
decreased HIF-1α protein level without modulating its mRNA expression. These data resemble those previously 
observed by our group in hypoxic non-tumor renal cells44 and by others in human colon adenocarcinoma HT-29 
Figure 5. HIF-1α silencing abolishes HT-dependent GLUT-1 upregulation but not AM and VEGF induction. 
(a) Representative immunoblot of HIF-1α knockdown with different concentrations of siHIF-1α. Effect of 
HIF-1α –silencing (siHIF-1α 40 nM) on the transcription level of (b) GLUT-1, (c) AM and (d) VEGF in 
hypoxic cells after treatment with HT 100 and 200 μM. Results are expressed as mRNA levels relative to Scr 
hypoxic cells after normalization against PPIA. Values represent the mean ± SD from three independent 
experiments. Statistically significant differences with the corresponding Scr-siRNA transfected hypoxic cells: 
ap < 0.05, aap < 0.01. Statistically significant differences with the corresponding HIF-1α-silenced cells: bp < 0.05, 
bbp < 0.01. Statistically significant differences with the corresponding HT treated-non-silenced cells: cp < 0.05, 
ccp < 0.01, cccp < 0.001.
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cells grown in vitro and in vivo in a xenograft model53, however the in vitro results were obtained after treat-
ment with much higher concentrations of this phenol (400–800 µM)54. Although HT induced no changes in 
NO levels in MCF-7 hypoxic cells, the down-regulation of HIF-1α by HT treatment can be attributed to the 
antioxidant effect of HT, which reactivates PHD activity. As mentioned above, PARP-1 protein and enzymatic 
activity have also been linked to lower HIF-1 levels14,47. In a skin carcinogenesis model, HIF-1α was one of the 
genes decreased after pharmacological inhibition of PARP-113. Although the particular mechanism underlying 
such effect has not been completely elucidated, the inhibition of inflammatory processes, and particularly of 
NF-κB, has been proposed to play a critical role. The PI3K/Akt/mTOR pathway, an upstream inducer of NFκB, 
can also regulate HIF-1α expression. Besides, mTOR activity is also modulated by PARP-1. Particularly, upon 
PARP-1 activation, AMPKα results PARylated and is exported to cytosol where it is phosphorylated by LKB1, 
a kinase presumably modified in a PARylation-dependent manner as well. Finally, the phosphorylated AMPKα 
inhibits mTOR55. According to the literature, the effect of HT on these pathways is controversial. Some authors 
have pointed that HT upregulates AMPK56 and inhibits Akt phosphorylation in tumor and non-tumor cells at 50, 
100 and 200 µM57–59. However, HT has also been shown to promote Akt phosphorylation60. The data presented 
here support the hypothesis that high concentrations of HT, shown to decrease PARylation, inhibit the activity of 
this pathway as lower levels of p-mTOR and p-S6 were observed in hypoxic 200 µM HT-treated cells. Altogether, 
these results suggest that the down-regulation of HIF-1α by HT is not only achieved post-translationally, through 
ROS decrease, but also at a translational level through the inhibition of the PI3K/Akt/mTOR pathway. This mod-
ulatory effect of HT could contribute to counteract breast cancer progression as high levels of PI3K, pAkt and 
p-mTOR are predictors of an adverse outcome in breast cancer patients61,62. Besides, autophagy, a process of cel-
lular self-digestion, is inhibited by mTOR activation and AMPK inhibition. The predictive value of autophagy for 
breast cancer prognosis remains unclear. However, inactivation of autophagy has been associated with shortened 
survival of breast cancer patients63 and the loss of autophagy-related genes increases the aggressive development 
of HER2-positive breast cancer64. Several reports point to HT as an inducer of autophagy65,66. Although the study 
of the effect of HT on autophagy in hypoxic conditions is beyond of this work, our results seem to indicate that 
HT could affect this process. Further studies would be necessary in order to demonstrate this effect.
HIF-1 plays a central role in the adaptive response to hypoxia. It therefore appears crucial to investigate the 
effect of HT in the expression of some HIF-1 target genes. The induction of angiogenesis and an increased glu-
cose uptake are two key molecular pathways that favor cell survival in a hypoxic environment. Those pathways 
are induced, among others, by the angiogenic factors VEGF and AM and by the metabolic proteins GLUT-1 and 
Figure 6. HT does not modulate HIF-2 but activates AHR at high concentrations. mRNA levels of Oct-4 (a), 
CYP1A1 (b) and AHRR (c). Results are expressed as mRNA expression relative to normoxic non HT-treated cells 
after normalization against PPIA. Values represent the mean ± SD from three independent experiments. Statistically 
significant differences with the corresponding non-treated normoxic cells: *p < 0.05. Statistically significant 
differences with the corresponding non-treated hypoxic cells: #p < 0.05, ##p < 0.01.
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LDH. As shown above, the treatment of MCF-7 cells with HT decreases the expression of HIF-1 α. Thus, we 
expected those genes to follow a similar pattern of response and to be down-regulated in HT-treated hypoxic 
cells. Our findings showed that HT exerts no effect on the mRNA levels of LDHA whereas, strikingly, high doses 
of this phenol up-regulates the transcription of AM, VEGF and GLUT-1, suggesting that HT does not reduce but 
induces the transcriptional activity of HIF-1. While this result does not match previous studies showing lower 
levels of VEGF in different models53,67,68, it supports our previous findings in renal cells44. FIH, through its ability 
to hydroxylate HIF-1α Asn-803, depresses HIF-1 transcriptional activity3. Thus, a plausible decrease in this pro-
tein could be responsible for the higher transcriptional activity of HIF-1. However, as the expression of FIH does 
not seem to be modulated by HT, we suggested that other regulatory pathways, different to HIF-1, are probably 
underlying the up-regulation of these genes. In order to corroborate the particular involvement of HIF-1 in the 
response of AM, VEGF and GLUT-1 to HT treatment, we silenced HIF-1α expression by siRNA. The induction 
of GLUT-1 by HT was completely abolished in these cells, suggesting that its up-regulation after HT treatment is 
Figure 7. ARNT seems to be involved in the effect of HT. (a) Immunoblot of ARNT knockdown with siARNT. 
Effect of ARNT silencing on the transcription level of (b) CYP1A1, (c) AM and (d) VEGF in hypoxic cells after 
treatment with HT 100 and 200 μM. Results are expressed as mRNA levels relative to Scr hipoxic cells after 
normalization against PPIA. Values represent the mean ± SD from three independent experiments. Statistically 
significant differences with the corresponding Scr hypoxic cells: ap < 0.05, aap < 0.01, aaap < 0.001. Statistically 
significant differences with the corresponding ARNT-silenced cells: bp < 0.05, bbp < 0.01, bbbp < 0.001. 
Statistically significant differences with the corresponding HT treated-non-silenced cells: cp < 0.05, ccp < 0.01, 
cccp < 0.001.
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highly dependent on HIF-1 transcriptional activity. However, AM and VEGF were only partially down-regulated, 
corroborating the involvement of other regulatory mechanisms, additional to HIF-1, in the HT-mediated induc-
tion of those genes. HIF-2 is another member of the HIF family also involved in the response to hypoxia. The 
effect of HT in the activity of this transcription factor is largely unknown. Hence, we wonder whether the reported 
increase in AM and VEGF could be mediated by HIF-269. To test this hypothesis, we assessed the impact of HT 
in the transcriptional activity of HIF-2. Erythropoietin or angiopoietin 2 are canonical HIF-2 targets but they 
are very poorly expressed in MCF-7 cells70, therefore we evaluated the mRNA levels of another specific HIF-2α 
target, Oct-471. HT did not affect Oct-4 transcription so HIF-2 does not seem to be involved in the response of 
AM and VEGF to HT. AM and VEGF can also be up-regulated by the hydrocarbon receptor (AHR)24,25,72,73. 
AHR is a cytoplasmic bHLH-PAS transcription factor that can be activated by diverse chemicals. Upon ligand 
binding, and similarly to HIF-1α, AHR is translocated to the nucleus where it dimerizes with HIF-β (ARNT) 
and forms an active transcription factor that regulates the expression of several genes involved in detoxifica-
tion, angiogenesis, cell proliferation, adhesion and migration, among others processes74. CYP1A1 is classically 
induced in response to AHR activation and, according to our results, the treatment of hypoxic MCF-7 cells with 
high concentrations of HT dramatically up-regulates the transcription of this protein involved in the metabolism 
of exogenous chemicals. These data appear to indicate that, at those concentrations, HT acts as an AHR ligand 
and promotes the expression of AM and VEGF through binding to their AHR-responsive elements. Although 
a complete view of the role of AHR in breast tumor growth is not currently available, AHR activation has been 
extensively linked with malignant transformation. In fact, a recent study in a cohort of 439 breast tumors showed 
that high AHR expression correlated with the up-regulation of genes involved in inflammation, metabolism, inva-
sion and growth factor signaling while high AHRR mRNA levels correlated with good-metastasis free survival26. 
Ligands for AHR are diverse and include not only pharmaceuticals but also dietary compounds such as phenols, 
natural and synthetic flavonoids75. The rank of concentrations at which those compounds exert such effect is 
highly variable and depends on the chemical structure but also on the biological model used76. Our structural 
modeling of HT binding to AHR supports that this phenol can act as an AHR ligand. In fact, the binding poses 
found show a π-π interaction proved to be crucial for TCDD binding, together with interactions with residues 
already shown to be important for TCDD binding to AHR36,39. Moreover, we also addressed the importance of 
concentration in the AHR agonist activity of HT, as only high levels of this phenol, clearly over its dietary intake, 
are able to induce CYP1A1. A deeper in silico analysis, going from less computationally intensive methods, like 
MMGBSA77, to other requesting much more computational resources such as alchemical free energy calcula-
tions78,79, should be necessary to shed light into the molecular basis of the different expected binding free energy 
of HT as compared to TCDD. However, the fact that the induction of AM and VEGF by HT is not completely 
abolished in ARNT-silenced cells suggests the involvement of other mechanisms additional to HIF-1 and AHR. 
ARNT2 is homologous to ARNT protein. Its expression is restricted to neural tissues and the kidney, but it is also 
found in multiple cancer cells. Although both ARNT and ARNT2 bind equally with HIF-α subunits, ARNT is 
much more efficient that ARNT2 in the AHR-mediated up-regulation of CYP1A180. Therefore, although further 
Figure 8. HT docked into human AHR as predicted by Autodock Vina (a,b) or BindScope (c), hydrogens 
other than those of the OH groups of HT are omitted for clarity. (d–f) 2D representations of the corresponding 
docked poses highlighting the interactions established between the ligand and the protein.
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experiments should be carried out, it could be hypothesized that the transcriptional effect of HT may be exerted 
through a combination of the AHR-ARNT and HIF-1α-ARNT/ARNT2 pathways.
To our knowledge, few papers compare the in vitro and in vivo antitumoral effect of HT in breast cancer. 
According to the literature, although very high concentrations of HT are necessary to inhibit the proliferation of 
breast cancer cells in vitro, a 0.5 mg HT/kg/day dose is able to significantly reduce breast tumor volume in rats81. 
In one study with breast cancer patients, 15 mg HT/day exerted a positive effect in women that received different 
cycles of combined chemotherapy of epirubicin and cyclophosphamide82. HT absorption is good but its total bio-
availability is only 5–10%. Therefore, although 100 or 200 µM are unachievable concentrations with diet intake or 
nutraceutical presentations of HT, the in vivo results seem to indicate that lower doses can attain similar results to 
those obtained in vitro with higher concentrations. The hypoxic environment is crucial in a tumoral context but 
its particular impact on in the response to anticancer treatments has been hardly analyzed. Our study aims to be 
a first step to shed light into the impact of hypoxia on the molecular response mediated by this phenol. The data 
we present appear to indicate that, in a hypoxic context, HT modulates different molecular mechanisms involved 
in tumor malignancy and resistance to therapy. The inhibition of the PI3K/Akt/mTOR pathway can overcome 
resistance to hormonal and anti-HER2 targeted therapies83, and HIF inhibitors are also promising molecules in 
cancer treatment84. Therefore, our data support that HT could have a chemomodulatory effect in breast cancer. 
It has already been shown, in an in vivo rat breast cancer model, that the co-treatment with paclitaxel and HT 
(0.5 mg/kg/day) decreases systemic oxidative stress, tumor volume and cell proliferation81. It would be plausible 
to hypothesize that some of the molecular mechanisms proposed here could underlie such response.
In conclusion, our results suggest that HT decreases the PI3K/Akt/mTOR pathway and HIF-1α in hypoxic 
MCF-7 cells. Moreover, we describe for the first time that high doses of HT, recurrently used in the literature, 
may act as an AHR agonist favoring the induction of angiogenic genes under hypoxic conditions. Therefore, our 
results provide new insights into the effect of HT in a hypoxic environment, and point to the importance of con-
centration in the comprehensive analysis of the biological potential of this compound.
Methods
Chemicals and reagents. HT (purity ≥98%) was obtained from Extrasynthese, France. Dulbecco’s mod-
ified Eagle’s medium (DMEM) and sodium pyruvate were from Capricorn Scientific, Germany, foetal bovine 
serum (FBS) was from Sigma, USA, and Trypan Blue Solution, 0.4% from Thermo Fisher, USA. Primary anti-
bodies mTOR (2972 S), p-mTOR (2971 S), S6 (2217 S) and p-S6 (2211 S) were purchased from Cell signaling 
Technology, USA; HIF-1α (A300–286A) from Bethyl, USA; PARP-1 (C-2-10) from Calbiochem, Germany; anti-
poly(ADP-ribose) (α-PAR) (4355-MC) from Trevigen, USA; α-Tubulin antibody (T5168) from Sigma, USA 
and FIH-1 (sc-26219) from Santa Cruz, USA. Apoptosis was quantified using the FITC Annexin V Apoptosis 
Detection Kit with PI (ANXVKF, Immunostep, Spain). RNA was isolated using the RNeasyPlus Mini kit (Qiagen, 
Germany). cDNA Synthesis Kit for RT-qPCR and iTaq UniverSYBR for Real-time PCR were from Bio-Rad, 
USA. Primers were synthesized by Biomedal S.L. (Spain). ARNT siRNA (s1613 and s1615), scramble siRNA 
(sc-37007) and the transfection reagent jetPRIME were from Ambion, Santa Cruz and Polyplus Transfection, 
USA, respectively. HIF-1α siRNA was from Sigma (forward 5′-CUGAUGACCAGCAACUUGA-3′, reverse 
5′-UCAAGUUGCUGGUCAUCAG-3′).
Cell culture and treatments. Human breast cancer MCF-7 cells were grown in 10% foetal bovine serum 
and 1% sodium pyruvate supplemented DMEM at 37 °C in 5% CO2 and 21% O2. Cells were pre-treated or not 
with different concentrations of HT, prepared in ethanol immediately before use, for 16 h under normoxic condi-
tions (21% O2), being cultured during the last 4 h either in normoxic or hypoxic conditions (1% O2). Control cells 
were treated with an equal ethanol concentration.
cell viability assay. The ratio of viable cells in each experimental condition was quantified by the trypan 
blue exclusion assay in a TC20™ Automated Cell Counter (BioRad, USA) according to manufacturer´s recom-
mendations. Cell viability was expressed as ratio of viable (non-stained) cells relative to normoxic non HT-treated 
cells.
Annexin V- propidium iodide double-staining assay. The induction of apoptosis in MCF-7 cells 
was evaluated by using a FITC Annexin V Apoptosis Detection Kit with propidium iodide (PI) (ANXVKF, 
Immunostep, Spain) according to the manufacturer’s protocol. Data acquisition and analysis were carried out 
using a flow cytometer (LSR Fortessa, BD Bioscience) and the BD FACSDivaTM software. Cells in upper left col-
umn (Q1) represent necrotic cells (Annexin V negative and PI positive cells); cells in upper right column (Q2) 
represent late apoptotic cells (Annexin V and PI positive cells); cells in lower left quadrant (Q3) represent viable 
cells (Annexin V and PI negative cells); cells in lower right quadrant (Q4) represent early apoptotic cells (Annexin 
V positive and PI negative cells).
Measurement of nitric oxide level. Nitric oxide (NO) level was indirectly quantified by determining 
nitrate/nitrite and S-nitroso compounds (NOx), using an ozone chemiluminescence-based method. For this pur-
pose, cells of each experimental condition were collected and lysed by 3 freeze–thaw cycles. After centrifugation 
at 14000 g for 30 min, the supernatants were collected and protein was quantified. Samples were deproteinized in 
a deproteinization solution (0.8 N NaOH and 16% ZnSO4). The total amount of NOx in the deproteinized samples 
was determined the purge system of Sievers Instruments, model NOA 280i. NOx concentrations were calculated 
by comparison with standard solutions of sodium nitrate. Final NOx values were referred to the total protein 
concentration in the initial extracts.
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Western blot. For western blot analysis, equal amounts of denatured total-protein extracts (20 μg) 
were loaded and separated on a 7.5% (HIF-1α, p-mTOR, α-PAR and PARP-1), or 10% (FIH-1 and p-S6) 
SDS-polyacrylamide gel. Proteins in the gel were transferred to a PVDF membrane (Amersham Pharmacia 
Biotech) and then blocked. Monoclonal antibodies to HIF-1α (1/5000), m-TOR (1/500), p-mTOR (1/1000), 
PARP-1 (1/1000), α-PAR (1/5000), FIH-1 (1/7000), S6 (1/1000), p-S6 (1/5000) and to α-tubulin (1/20.000), as 
a loading control, were used for detection of the respective proteins. Antibody reaction was revealed by means 
of chemiluminescence detection procedures according to the manufacturer’s recommendations (ECL kit, 
Amersham Corp). Western-blot was quantified by using TotalLab software.
Quantitative Real-time pcR (qRt-pcR). Real-time PCR was performed in a CFX384 Touch Real-Time 
PCR Detection System (Bio-Rad) using iTaq UniverSYBR. The sequences of the primers are below: HIF-1α, forward 
5′-TGCTTTAACTTTGCTGGCCC-3′, reverse 5′-GTTTCTGTGTCGTTGCTGCC-3′; AM, forward 5′-CTCTG 
AGTCGTGGGAAGAGG-3′, reverse 5′-CCCTGGAAGTTGTTCATGCT-3′; VEGF, forward 5′-TTGTACAAG 
ATCCGCAGACG-3′, reverse 5′-TCACATCTGCAAGTACGTTCG-3′; GLUT-1, forward 5′-AGGCTTCT 
CCAACTGGACCT-3′, reverse 5′-CCTCGGGTGTCTTGTCACTT-3′; LDHA, forward 5′-AGGCTACACATC 
CTGGGCTA-3′, reverse 5′-CCCAAAATGCAAGGAACACT-3′; Oct-4, forward 5′-GGCTCGAGAAGGATGT 
GGTC-3′, reverse 5′- CCAGCAGACACCTTAGACGA-3′; AHRR, forward 5′-GAAGGAGCAGCAGAG 
AGAGC-3′, reverse 5′- CTTTGTGGGTCCTGGAGTCT-3′; CYP1A1, forward 5′-CAAGGGGCGTTGTGTC 
TTTG-3′, reverse 5′- GTCGATAGCACCATCAGGGG-3′; PPIA, forward 5′-TTCATCTGCACTGCCAAGAC-3′, 
reverse 5′- TCGAGTTGTCCACAGTCAGC-3′. Experiments were performed in triplicate, and the relative quan-
tities of target genes, corrected with the normalizing gene PPIA, were calculated using the Bio-Rad CFX Manager 
Software.
HIF-1α and ARNT siRNA transfection. HIF-1α, ARNT and Scr siRNAs were transfected with transfec-
tion reagent according to the manufacturer’s instructions. Briefly, MCF-7 cells (11 × 104/well) were plated into 
6-well plates, allowed to adhere for 24 h and incubated with the siRNAs for 24 h. Different concentrations of each 
siRNA were initially tested (20, 40 and 60 nM of siHIF-1α; 5, 10 and 25 nM of siARNTs). Finally, siHIF-1α 40 nM, 
siARNTs 25 nM and similar concentrations of Scr-siRNA were used. Two pairs of ARNT siRNAs were used to 
ensure a maximum silencing. The transfection medium was then replaced with fresh medium for 24 h before 
further treatment with HT and/or hypoxia. The efficiency of silencing was evaluated by western-blot analysis of 
HIF-1α and ARNT.
Modelling of HT binding to AHR. The model of the human AHR PAS-B domain was obtained by homol-
ogy modelling using as templates three holo structures of the HIF-2α PAS-B domain, with PDB IDs 3F1O30, 
3H7W31 and 3H8285. The Prime module of the Schrödinger Maestro 2017-1 suite was used to obtain an homology 
model using the Consensus Homology Model, using as query sequence residues 284–390 of human AHR. The 
model was subsequently loaded into the web program ProteinPrepare86, which protonates at pH=7 and opti-
mizes the hydrogen bond network. The model for HT was manually drawn and imported into UCSF Chimera87, 
where its structure was optimized for 100 steepest-descent followed by 100 conjugate-gradient steps. The HR 
model, together with the human AHR one, were on the one hand uploaded into Bindscope34, and on the other 
one prepared with the DockPrep utility of Chimera to be used in a docking calculation with Autodock Vina33. 
Amber ff14SB88 charges were used for the protein, whilst AM1-BCC89,90 charges were assigned to HT. The bind-
ing pocket used, which is the same found in other docking experiments, was determined with DeepSite91. The 
cartesian coordinates of the center of the binding pocket found with DeepSite were used to define a search box 
for Autodock Vina of 10×10×10 Å3, and for other parameters, defaults were used. Figures were rendered with 
UCSF Chimera and Maestro.
Statistical analysis. Data are expressed as means ± SD of at least three independent experiments. Statistical 
comparisons between the different experimental groups and their corresponding controls were made with 
Student’s t-test, accepting p < 0.05 as the level of significance, using GraphPad Prism 6 software (GraphPad 
Software Inc.).
Experimental methods guidelines statement. All experiments were performed in accordance with 
relevant guidelines and regulations.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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